About Carbylan
Carbylan is a company based in Palo Alto (United States) founded in 2004. Carbylan has raised $42.9 million across 6 funding rounds from investors including Alta Partners, InterWest and Vivo Capital. The company has 7 employees as of December 31, 2022. Carbylan operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Palo Alto, United States
- Employees 7 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kalvista Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$42.9 M (USD)
in 6 rounds
-
Latest Funding Round
$4 M (USD), Series C
Mar 05, 2015
-
Investors
Alta Partners
& 2 more
-
Employee Count
7
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Carbylan
Carbylan is a publicly listed company on the NASDAQ with ticker symbol KALV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Carbylan
Unlock access to complete
Unlock access to complete
Leadership Team
38 people
Sales and Marketing
9 people
Operations Team
5 people
Finance and Accounting
5 people
Software Development Team
5 people
Senior Team
4 people
Human Resources and Administration
4 people
Product Management Team
3 people
Unlock access to complete
Funding Insights of Carbylan
Carbylan has successfully raised a total of $42.9M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $4 million completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Carbylan
Carbylan has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Alta Partners, InterWest and Vivo Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on healthcare companies
|
Locked | Locked | Locked | |
|
Early-stage investing in IT and healthcare ventures.
|
Locked | Locked | Locked | |
|
Venture capital and private equity firm
|
Locked | Locked | Locked |
Investor details for Carbylan
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Carbylan
Investment portfolio details for Carbylan
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Carbylan
Detailed financials for Carbylan
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Carbylan Comparisons
Peer comparison for Carbylan
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Carbylan
Carbylan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Carbylan
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Carbylan
Complete news archive for Carbylan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Carbylan
Carbylan was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Carbylan is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Carbylan is a funded company, having raised a total of $42.9M across 6 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Carbylan is 7.
Carbylan develops therapeutics using polymers of hyaluronic acid. Its proprietary technology enables the crosslinking of hyaluronic acid to form hydrogels. Its lead candidate Hydros-TA is a low dose steroid - hydrogel formulation for pain management with symptomatic osteoarthritis (Phase 3). In Apr 2016, Carbylan pulls pain drug Phase 3 trial and puts itself up for sale. As of Nov 2016, Carbylan Therapeutics was acquired by KalVista Pharmaceuticals in a reverse merger transaction.
Carbylan's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Yes, Carbylan is publicly traded on NASDAQ under the ticker symbol KALV.
Carbylan has 3 investors. Key investors include Alta Partners, InterWest, and Vivo Capital.
The ticker symbol of Carbylan is KALV on NASDAQ.